Catherine Bornbaum, PhD, MBA, Head of Clinical Operations and Partnerships at RetiSpec discusses using hyperspectral retinal imaging and artificial intelligence to diagnose Alzheimer’s disease before the onset of symptoms. RetiSpec’s proprietary technology integrates seamlessly with an optometrist’s camera creating a new workflow from optometrist to neurologist. It provides a whole picture of disease diagnosis, is much cheaper than current methods, noninvasive, and will be of great value to Pharma as they rely on early diagnosis to recruit patients for Alzheimer’s clinical trials.
Catherine is a health scientist and MBA with 10+ years of experience leading large-scale health research operations. In 2019, she was named one of the 100 Best & Brightest Executive MBAs globally by Poets & Quants.